![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Article |
|---|---|
| Title: | BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia |
| Creators: |
Korenkov, M.  ORCID: https://orcid.org/0000-0002-2988-8483, Zuleeg, M. R. ORCID: https://orcid.org/0009-0002-9947-5585, Liebaert, J., Fregona, V. ORCID: https://orcid.org/0000-0003-4857-1737, Serve, S. ORCID: https://orcid.org/0000-0002-9839-7119, Jesse, J., Böckle, D. ORCID: https://orcid.org/0000-0002-1783-9641, Bohl, S. ORCID: https://orcid.org/0000-0001-9379-3342, Damm, F. ORCID: https://orcid.org/0000-0001-5553-1173, Bullinger, L. ORCID: https://orcid.org/0000-0002-5890-5510, Keller, U. ORCID: https://orcid.org/0000-0002-8485-1958, Busse, A. ORCID: https://orcid.org/0000-0002-3470-6947, Schwarzer, A., Albach, F. ORCID: https://orcid.org/0000-0002-2697-9080, Thiele, T. ORCID: https://orcid.org/0000-0003-0177-6508, Haas, S. ORCID: https://orcid.org/0000-0001-9227-2051, Krönke, J. ORCID: https://orcid.org/0000-0002-4649-0506 and Hütter-Krönke, M. L. ORCID: https://orcid.org/0000-0002-4531-9889
|
| Abstract: | Immune thrombocytopenia (ITP) is an autoimmune disease mediated by platelet-reactive antibodies, leading to accelerated platelet clearance and an increased risk of bleeding. Despite multiple available therapeutic options, durable treatment-free remissions remain uncommon in patients with refractory disease. Here, we report three patients with multi-drug refractory ITP treated with a bispecific BCMA-targeting T-cell engager, teclistamab, approved for the treatment of multiple myeloma. Fixed-duration teclistamab therapy induced platelet response within 4, 9, and 23 days, which was sustained after treatment discontinuation. The entirety of ITP-directed therapies was tapered and discontinued, and the three patients remain in treatment-free remission for 8, 6 and 3 months, respectively. Responses were associated with rapid depletion of B cells and plasma cells. Toxicity was manageable and largely limited to low-grade cytokine release syndrome, transient neutropenia, infections that were readily controlled. These observations highlight BCMA-directed bispecific antibodies as a potential therapeutic strategy in autoimmune hematologic diseases and provide a rationale for prospective clinical trials. |
| Keywords: | Immune Thrombocytopenia, Evans Syndrome, BCMA T-Cell-Engager |
| Source: | Blood Immunology & Cellular Therapy |
| ISSN: | 3050-5976 |
| Publisher: | Elsevier |
| Page Range: | 100062 |
| Number of Pages: | 1 |
| Date: | 20 May 2026 |
| Official Publication: | https://doi.org/10.1016/j.bict.2026.100062 |
Repository Staff Only: item control page
